Nephrotic syndrome due to primary systemic AL amyloidosis, successfully treated with VAD (vincristine, doxorubicin and dexamethasone) alone

Internal Medicine

Volumn 47, Issue 6, 2008, Pages 543-549

  Matsuda, Masayuki ^a   Gono, Takahisa ^a   Katoh, Nagaaki ^a   Yoshida, Takuhiro ^a   Tazawa, Ko Ichi ^a   Shimojima, Yasuhiro ^a   Ishii, Wataru ^a   Fushimi, Tomohisa ^a   Ikeda, Shu Ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

M protein; Nephrotic syndrome; Primary systemic AL amyloidosis; VAD

Indexed keywords

ALPHA INTERFERON; DEXAMETHASONE; DIPYRIDAMOLE; DIURETIC AGENT; DOXORUBICIN; M PROTEIN; MELPHALAN; PREDNISOLONE; VINCRISTINE; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG; VAD I PROTOCOL;

ABDOMINAL DISTENSION; ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CASE REPORT; CONSTIPATION; CONTINUOUS INFUSION; DRUG MEGADOSE; EDEMA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; MALE; NEPHROTIC SYNDROME; PROTEINURIA; RELAPSE; MIDDLE AGED;

AGED; AMYLOIDOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; VINCRISTINE;

EID: 41649104969     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0709     Document Type: Article

References (21)

1. Kyle RA, Gertz MA. Primary systemic amyloidosis. Clinical and laboratory features in 474 cases. Semin Hematol 32: 45-59, 1995.
2. Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 28: 637-642, 2001.
3. Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 113: 540-555, 2002.
4. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 42: 4276-4282, 2002.
5. Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 101: 766-769, 1998.
6. Mollee P. Wechalekar AD, Pereira DL, et al. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant 33: 271-277, 2004.
7. Gertz MA, Lacy MQ, Gastineau DA, et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 26: 963-969, 2000.
8. Gono T, Matsuda M, Shimojima Y, et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid 11: 245-256, 2004.
9. van Gameren II, Hazenberg BPC, Jager PL, Smit JW, Vellenga E. AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid 9: 165-174, 2002.
10. Sezer O, Schmid P, Schweigert M, et al. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplant 23: 967-969, 1999.
11. Wardley AM, Jayson GC, Goldsmith DJA, Venning MC, Ackrill P, Scarffe JH. The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer 78: 774-776, 1998.
12. The Guidelines Working. Group of the UK Myeloma Forum. Guidelines on the diagnosis and management of AL amyloidosis. 2004 United Kingdom Myeloma Forum 125: 681-700, 2004.
13. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges-for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48: 1437-4444, 2000.
14. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 119: 274-278, 2003.
15. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122: 78-84, 2003.
16. Matsuda M, Yamada T, Gono T, et al. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis. Intern Med 44: 428-433, 2005.
17. Clark RJ, Kitzmann JA, Abraham RS, Lymph IF, Kyle RA, Bradwell AR. Detection of monoclonal free light chains by nephelometry: normat ranges and relative sensitivity. Clin Chem 47: a27, 2001.
18. Matsuda M, Gono T, Shimojima Y, Hoshii Y, Ikeda S. Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis. Amyloid 10: 110-116, 2003.
19. Matsuda M, Gono T, Shimojima Y, Sakashita K, Koike K, Ikeda S. Evaluation of intensive chemotherapy in AL amyloidosis: usefulness of flow cytometric analysis of plasma cells in bone marrow. Amyloid 10: 250-256, 2003.
20. Dhodapkar MV, Jagannath S, Vesole D, et al. Treatment of AL-amyloidosis with dexamethasone plus alpha, interferon. Leuk Lymphoma 27: 351-356, 1997.
21. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients, with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103: 2936-2938, 2004.